DekaBank Deutsche Girozentrale’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-60,000
| Closed | -$1.61M | – | 1311 |
|
|
2025
Q4 | $1.61M | Hold |
60,000
| – | – | ﹤0.01% | 801 |
|
|
2025
Q3 | $1.59M | Hold |
60,000
| – | – | ﹤0.01% | 790 |
|
|
2025
Q2 | $1.61M | Hold |
60,000
| – | – | ﹤0.01% | 784 |
|
|
2025
Q1 | $1.48M | Hold |
60,000
| – | – | ﹤0.01% | 780 |
|
|
2024
Q4 | $1.4M | Hold |
60,000
| – | – | ﹤0.01% | 812 |
|
|
2024
Q3 | $1.48M | Hold |
60,000
| – | – | ﹤0.01% | 819 |
|
|
2024
Q2 | $1.48M | Hold |
60,000
| – | – | ﹤0.01% | 813 |
|
|
2024
Q1 | $1.48M | Hold |
60,000
| – | – | ﹤0.01% | 807 |
|
|
2023
Q4 | $560K | Hold |
60,000
| – | – | ﹤0.01% | 1013 |
|
|
2023
Q3 | $394K | Hold |
60,000
| – | – | ﹤0.01% | 1074 |
|
|
2023
Q2 | $665K | Buy |
60,000
+36,000
| +150% | +$452K | ﹤0.01% | 969 |
|
|
2023
Q1 | $403K | Hold |
24,000
| – | – | ﹤0.01% | 1055 |
|
|
2022
Q4 | $544K | Buy |
+24,000
| New | +$358K | ﹤0.01% | 1016 |
|
|
2022
Q2 | – | Sell |
-15,800
| Closed | -$285K | – | 1417 |
|
|
2022
Q1 | $285K | Buy |
15,800
+1,400
| +10% | +$23.8K | ﹤0.01% | 1157 |
|
|
2021
Q4 | $334K | Buy |
14,400
+400
| +3% | +$9.55K | ﹤0.01% | 1178 |
|
|
2021
Q3 | $324K | Hold |
14,000
| – | – | ﹤0.01% | 1125 |
|
|
2021
Q2 | $320K | Hold |
14,000
| – | – | ﹤0.01% | 1136 |
|
|
2021
Q1 | $284K | Hold |
14,000
| – | – | ﹤0.01% | 1124 |
|
|
2020
Q4 | $384K | Buy |
+14,000
| New | +$408K | ﹤0.01% | 1077 |
|
Other funds holding RNAM
DekaBank Deutsche Girozentrale's RNAM Position: Q1 2026 in Review
DekaBank Deutsche Girozentrale sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 60,000 shares — an estimated $1.61M sold.
DekaBank Deutsche Girozentrale first reported a position in RNAM in Q4 2020 and held it in 19 quarters. The position peaked at $1.61M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- DekaBank Deutsche Girozentrale reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- DekaBank Deutsche Girozentrale sold 60,000 Avidity Biosciences shares in Q1 2026, an estimated $1.61M.
- DekaBank Deutsche Girozentrale first reported a position in Avidity Biosciences in Q4 2020 and held it in 19 quarters.
- DekaBank Deutsche Girozentrale's Avidity Biosciences position peaked at $1.61M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.